Novartis begins shipment of Fluvirin seasonal influenza vaccine for the U.S. market ahead of schedule
Providing 30 million doses of Fluvirin vaccine in the U.S., to support the annual seasonal influenza vaccination campaign
Novartis Vaccines has started shipping seasonal influenza vaccine to U.S. healthcare facilities for the 2009-2010 season. The company delivered Fluvirin® influenza virus vaccine, which has been approved by the U.S. food and Drug Administration (FDA), to the U.S. weeks ahead of schedule in anticipation of the increased demand for seasonal influenza vaccine created by the current global (A) H1N1 influenza pandemic.
"With the (A) H1N1 influenza pandemic underway, it is important that we take every possible precaution to help protect U.S. citizens from all circulating strains of influenza," said Andrin Oswald, CEO of Novartis Vaccines and Diagnostics. "By receiving the seasonal influenza vaccine early, physicians and public health officials can better prepare for the upcoming flu season."
Novartis Vaccines will provide the U.S. market with approximately 30 million doses of Fluvirin vaccine, indicated for patients 4 years and older. Fluvirin vaccine contains antigens to the three influenza virus strains for this year's vaccine recommended by the World Health Organization (WHO):
- A/Brisbane/59/2007, IVR-148 (H1N1)
- A/Uruguay/716/2007, NYMC X-175C (H3N2) (an A/Brisbane/10/2007-like virus)
- B/Brisbane/60/2008
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Last viewed contents

Oncoethix - Lausanne, Switzerland
IRCM researchers fuel an important debate in the field of molecular biology

Conductors in the molecule: LIKAT simplifies method that prevents premature degradation of drugs in the body - Chemical process of deuteration greatly simplified
Intana Announces Agreement to Provide Proprietary Spectroscopy Technology

The gene to which we owe our big brain - Brain organoids provide insights into the evolution of the human brain

Biotechnology start-up using AI to translate nature into new medicines - Enveda Biosciences announces $55M in new funding to accelerate platform and advance multiple candidates to clinical trials

The role of the tunnel

From Biopaste to Bioplastic - Forest scientists develop innovative wood-based materials for 3D printing
History of Human Migration to be Mapped - Applied Biosystems Joins the Genographic Project to Support Landmark Population Genetics Study Mapping the History of Human Migration
Jury Finds In Favor Of Monsanto In Patent Case Involving Bayer CropScience And Insect-Protected Corn Technology
Category:Lettuce_diseases
